Reconstruction of anti-leprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and CratEDTA (a source of C3-C9).
This paper describes the mechanism of in vitro interaction of human serum complement system with anti-leprosy drugs (dapsone and clofazimine) and anti-lepra reaction drugs such as chloroquine. These drugs could inhibit the complement-mediated lysis of erythrocytes both via direct and alternative pathways, but only at hypertherapeutic doses. Attempts were made to restore the drug depleted complement-mediated lysis of erythrocytes by adding zymosan-treated guinea-pig sera (a source of C142) and also by adding Crat-EDTA sera (a source of C3-C9). Destroyed complement-mediated haemolytic activity by dapsone could be restored by early complement (C142) components, while complement-mediated haemolytic activity blocked by clofazimine could be regenerated by adding both late (C3-C9) and early (C142) complement component. However, chloroquine-mediated inhibition of the complement-mediated haemolysis activity could not be appreciably restored by adding both early and late complement reagents.
Kashyap
A
A
Department of Immunology and Microbiology, Vallabhbhai Patel Chest Institute, Delhi, India.
Saha
K
K
Sehgal
V N
VN
D000818:Animals; D002738:Chloroquine / Q000494:pharmacology*; D002991:Clofazimine / Q000494:pharmacology*; D003167:Complement Activation; D003165:Complement System Proteins / Q000187:drug effects* / Q000276:immunology; D003622:Dapsone / Q000494:pharmacology*; D004492:Edetic Acid / Q000494:pharmacology; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D051381:Rats; D015054:Zymosan / Q000494:pharmacology*
D002738:Chloroquine; D003622:Dapsone; D003165:Complement System Proteins; D015054:Zymosan; D004492:Edetic Acid; D002991:Clofazimine